title: [Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection].
abstract: Most colorectal cancer patients with liver metastases are not resectable upon initial diagnosis. Recently, chemotherapy improves overall survival of initially unresectable patients by allowing tumor downstaging and complete resection. We report a FOLFOX-refractory rectal cancer patient with unresectable multiple liver metastases, whose tumors could be downstaged and completely resected after initiation of FOLFIRI with cetuximab.
  
  
  METHODS
  A 41-year-old male demonstrated rectal cancer with unresectable multiple liver metastases. He was treated by FOLFOX4 therapy as first-line chemotherapy. After initiating 14 courses, he was treated by FOLFIRI with cetuximab because of disease progression. After initiation of chemotherapy, radiographic examination demonstrated remarkable reduction of primary rectal tumor and metastatic liver tumors. He underwent complete rectal tumor resection after 13 courses of chemotherapy, and metastatic liver tumor resection after 18 courses of chemotherapy.
authors.affiliation: Dept. of Medical Oncology and Hematology, Cancer Institute Hospital, Japanese Foundation for Cancer Research.
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Mitsuhashi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Matsusaka
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Mizunuma
authors.forename: Takashi
authors.initials: T
authors.lastname: Ichimura
authors.forename: Masato
authors.initials: M
authors.lastname: Ozaka
authors.forename: Mariko
authors.initials: M
authors.lastname: Ogura
authors.forename: Eiji
authors.initials: E
authors.lastname: Shinozaki
authors.forename: Mitsukuni
authors.initials: M
authors.lastname: Suenaga
authors.forename: Keisho
authors.initials: K
authors.lastname: Chin
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Fujimoto
authors.forename: Akio
authors.initials: A
authors.lastname: Saiura
authors.forename: Noriko
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Hatake
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D019008:Drug Resistance, Neoplasm; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000494:pharmacology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery*; D008297:Male; D009944:Organoplatinum Compounds / Q000494:pharmacology; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin